Argen X SE

(ARGNF)

By |

Profile

argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-111, ARGX-109, ARGX-115, ARGX-112, and others. The company operates in the Netherlands, Germany, Denmark, Belgium, Switzerland, the United States, and Luxembourg. It derives the majority of its revenues from Switzerland.

Contact Information

Website: www.argenx.com
Email: info@argenx.com
Main Phone: +31 763030488
Address: Willemstraat 5
City / Town: Breda
Country: NL
Postal Code: 4811 AH

Issuer Information

Exchange: GREY
CEO: Tim Van Hauwermeiren
Employees: 188

Equities News

Profile

argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-111, ARGX-109, ARGX-115, ARGX-112, and others. The company operates in the Netherlands, Germany, Denmark, Belgium, Switzerland, the United States, and Luxembourg. It derives the majority of its revenues from Switzerland.

Contact Information

Website: www.argenx.com
Email: info@argenx.com
Main Phone: +31 763030488
Address: Willemstraat 5
City / Town: Breda
Country: NL
Postal Code: 4811 AH

Issuer Information

Exchange: GREY
CEO: Tim Van Hauwermeiren
Employees: 188

Equities News

$ 242.13 $ 0. (0.00%)
Last Price 242.13 Change $ 0. Change % 0.00 Tick N/A
Bid N/A Bid Size 0.00 Ask N/A Ask Size 0.00
Open N/A High N/A Low N/A Prev Close 242.13
Last Trade Volume 0 52 Wk Hi 256.35 52 Wk Low 130.01
Market Cap 11.4 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 47,108,499.00 EPS (TTM) -2.29 PE Ratio -27.80 Exchange Greys